Pacer Advisors Inc. increased its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 23.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,672 shares of the life sciences company’s stock after acquiring an additional 1,436 shares during the period. Pacer Advisors Inc.’s holdings in Integra LifeSciences were worth $387,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Chartwell Investment Partners LLC raised its stake in Integra LifeSciences by 115.6% in the third quarter. Chartwell Investment Partners LLC now owns 90,625 shares of the life sciences company’s stock valued at $4,574,000 after buying an additional 48,599 shares in the last quarter. SG Americas Securities LLC raised its stake in Integra LifeSciences by 21.8% in the third quarter. SG Americas Securities LLC now owns 20,669 shares of the life sciences company’s stock valued at $1,043,000 after buying an additional 3,700 shares in the last quarter. Sector Gamma AS raised its stake in Integra LifeSciences by 7.3% in the third quarter. Sector Gamma AS now owns 529,230 shares of the life sciences company’s stock valued at $26,716,000 after buying an additional 36,000 shares in the last quarter. Comerica Bank raised its stake in Integra LifeSciences by 5.0% in the third quarter. Comerica Bank now owns 67,723 shares of the life sciences company’s stock valued at $3,139,000 after buying an additional 3,195 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Integra LifeSciences by 3.9% in the third quarter. Rhumbline Advisers now owns 135,998 shares of the life sciences company’s stock valued at $6,865,000 after buying an additional 5,136 shares in the last quarter. Institutional investors and hedge funds own 87.59% of the company’s stock.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at $49.09 on Monday. The company has a current ratio of 4.49, a quick ratio of 3.39 and a debt-to-equity ratio of 1.26. Integra LifeSciences Holdings Corporation has a 52-week low of $37.71 and a 52-week high of $56.42. The company has a market capitalization of $3,852.44, a PE ratio of 27.12, a PEG ratio of 2.15 and a beta of 0.65.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, October 26th. The life sciences company reported $0.45 EPS for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). Integra LifeSciences had a return on equity of 16.35% and a net margin of 4.52%. The firm had revenue of $278.83 million for the quarter, compared to analyst estimates of $286.00 million. During the same quarter last year, the firm posted $0.93 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. research analysts forecast that Integra LifeSciences Holdings Corporation will post 1.85 EPS for the current fiscal year.

In related news, Director Barbara B. Hill purchased 10,768 shares of the stock in a transaction that occurred on Tuesday, October 31st. The shares were purchased at an average price of $46.66 per share, with a total value of $502,434.88. Following the completion of the acquisition, the director now directly owns 55,540 shares in the company, valued at approximately $2,591,496.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Richard D. Gorelick sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total value of $70,785.00. Following the transaction, the vice president now directly owns 21,665 shares in the company, valued at approximately $1,022,371.35. The disclosure for this sale can be found here. Company insiders own 21.50% of the company’s stock.

IART has been the topic of a number of analyst reports. Jefferies Group restated a “buy” rating on shares of Integra LifeSciences in a research note on Sunday, September 10th. Barclays restated an “equal weight” rating and issued a $53.00 price target (up from $47.00) on shares of Integra LifeSciences in a research note on Tuesday, September 12th. Oppenheimer restated a “buy” rating and issued a $60.00 price target on shares of Integra LifeSciences in a research note on Monday, September 18th. Zacks Investment Research upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $57.00 target price on the stock in a research report on Tuesday, October 3rd. Finally, J P Morgan Chase & Co cut Integra LifeSciences from an “overweight” rating to a “neutral” rating and set a $44.00 target price on the stock. in a research report on Friday, October 27th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $53.82.

TRADEMARK VIOLATION NOTICE: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/12/04/pacer-advisors-inc-has-387000-stake-in-integra-lifesciences-holdings-corporation-iart.html.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.